Effective Treatment Solutions for Parkinson Disease

Mary Maral Mouradian, M.D.
William Dow Lovett Professor of Neurology
Director, Center for Neurodegenerative and Neuroimmunologic Diseases
Director of Research, Department of Neurology

CURRENT RESEARCH
Understanding molecular pathways of Parkinson disease and identifying novel targets to develop effective treatments

Wouldn’t it be terrific to have drugs that fully control all the symptoms of Parkinson disease (PD), prevent the complications of currently available treatments, and -- better yet -- slow down disease progression? That’s what patients who suffer from this chronic disabling disorder, their physicians, and the scientific community hope for. Dr. Mary Maral Mouradian, William Dow Lovett Professor of Neurology and Director of the Center for Neurodegenerative and Neuroimmunologic Diseases at Rutgers Biomedical Health Sciences – Robert Wood Johnson Medical School, studies the basic problems that underlie the neurodegeneration in PD and its treatment complications, to identify strategies to interfere with these processes, and develop new drugs that have the potential to impact patients’ quality of life.

Editor-in-Chief of a prestigious scientific journal, Neurotherapeutics who has served on a number of national and international research granting agencies, Dr. Mouradian leads a multidisciplinary team of molecular biologists, chemists, and neurologists in identifying new strategies to target the pathologic protein that misfolds and aggregates in the brains of patients with PD with the goal to slow the course of the disease and prevent symptom progression. Her team has also identified a drug that can amend the complications of existing treatments.

Currently, Dr. Mouradian and her team continue to investigate various therapeutic approaches and compounds that are at different stages of development, ranging from testing them at the laboratory bench in cells, to validating their efficacy in animal models of the disease, and at least one compound is ready for a clinical trial.

Dr. Mouradian and her team...

Read More at benefunder.com/

AFFILIATION
Rutgers University

EDUCATION
- Postdoctoral training in Molecular Biology 1990, National Heart, Lung and Blood Institute, NIH
- Fellowship in Experimental Therapeutics in 1988, National Institute of Neurological Disorders and Stroke, NIH
- Neurology Residency in 1985, University of Cincinnati Medical Center
- M.D. with Distinction, Alpha Omega Alpha in 1982, American University of Beirut
- B.S. in Biology – Chemistry with High Distinction 1978, American University of Beirut

AWARDS
- Outstanding Medical Research Scientist Award, 2015
- Excellence in Research Award, 2013
- Roger Duvoisin Research Scholar Award, 2003
- NIH Award of Merit 1992
- Alpha Omega Alpha Honor Medical Society elected member 1981

RESEARCH AREAS
Life Science, Neurological / Cognitive

FUNDING REQUEST
Your contributions will support Dr. Mary Maral Mouradian and her team at Rutgers Biomedical and Health Sciences as they investigate innovative therapeutic approaches for Parkinson disease. Donations will help fund the $1M/year over five years for preclinical and translational studies to validate therapeutic targets and test new compounds in the laboratory and animal models, and $2.5M for an initial clinical trial, helping to improve patients’ quality of life and impact significant societal savings.